Eisai scores FDA priority review for bigger Lenvima use in kidney cancer

Eisai's thyroid cancer drug Lenvima stepped into the FDA's fast lane for a new use. The agency granted Lenvima priority review as a treatment for advanced kidney cancer, which could be a much more lucrative indication. More than 61,000 patients will be diagnosed with kidney cancer this year, Eisai says; the approval would cover Lenvima in combination with Novartis' ($NVS) Afinitor in patients who've failed on previous VEGF therapy. Release

Suggested Articles

Despite a veritable graveyard of drug prospects in hard-to-treat glioblastoma, Bayer hopes underperforming Stivarga can crack the code in new trials.

Online pharmacy Valisure has criticized the FDA for what it deems as irrational standards in the levels of suspected carcinogens in the drug supply.

GSK is grouping some non-core consumer products into three portfolios for sell-offs so it can win EU antitrust clearance for its Pfizer deal.